文献速递呼吸衰竭与机械通气创伤与烧伤重症综合管理与镇静镇痛

肾素抑制剂阿利吉仑保护大鼠肺免受脂肪栓塞的组织病理学影响

The renin inhibitor aliskiren protects rat lungs from the histopathologic effects of fat embolism.
PubMed 文献 · J Trauma Acute Care Surg · 2017-01-01
一句话结论大鼠脂肪栓塞模型中,阿利吉仑50或100 mg/kg腹腔注射可减轻肺纤维化、脂肪沉积和血管腔狭窄,作者认为可能用于预防和治疗。

本研究在大鼠脂肪栓塞模型(静脉注射三油酸甘油酯)中,于造模后1小时腹腔注射生理盐水或阿利吉仑50或100 mg/kg,48小时处死后行肺组织学检查。结果显示三油酸甘油酯组出现显著纤维化(三色染色和α-平滑肌肌动蛋白染色均p<0.0001)、脂肪增加(p=0.0006)和血管腔通畅度降低;阿利吉仑阻断纤维化至与对照组无差异(两种染色均p<0.0001),低剂量和高剂量均减少脂肪滴大小、分布和数量(低剂量p=0.0095,高剂量p=0.0028),低剂量阻止血管腔通畅度降低(p=0.0058)。作者认为阿利吉仑在骨科手术前预防性使用和严重创伤后治疗性使用可能预防严重肺部病理后遗症。

要点

  • 大鼠脂肪栓塞模型造模后1小时腹腔注射阿利吉仑50或100 mg/kg,48小时肺组织学显示纤维化被阻断至与对照组无差异(三色染色和α-平滑肌肌动蛋白染色均p<0.0001)。
  • 三油酸甘油酯组肺脂肪显著增加(p=0.0006),阿利吉仑低剂量(p=0.0095)和高剂量(p=0.0028)均减少脂肪滴大小、分布和数量。
  • 低剂量阿利吉仑阻止三油酸甘油酯引起的血管腔通畅度降低(p=0.0058)。
  • 作者认为临床意义包括在特定骨科手术前预防性使用阿利吉仑,以及在严重创伤后治疗性使用,以预防严重肺部病理后遗症。

适用人群与场景

  • 无麻醉大鼠静脉注射中性脂肪三油酸甘油酯诱导脂肪栓塞模型,用于评估肺组织病理学改变。

处置流程与药物剂量

  • 脂肪栓塞诱导后1小时腹腔注射阿利吉仑50 mg/kg或100 mg/kg,或生理盐水对照;48小时处死大鼠取肺行组织学染色检查。

研究设计与关键结果

  • 研究类型为大鼠脂肪栓塞模型实验;三油酸甘油酯组肺纤维化标志物(三色染色和α-平滑肌肌动蛋白染色)显著增加(均p<0.0001),阿利吉仑治疗组纤维化降至与对照组无差异(均p<0.0001)。
  • 三油酸甘油酯组肺脂肪显著增加(p=0.0006);阿利吉仑低剂量(p=0.0095)和高剂量(p=0.0028)均减少脂肪滴大小、分布和数量。
  • 低剂量阿利吉仑阻止三油酸甘油酯引起的血管腔通畅度降低(p=0.0058)。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠脂肪栓塞模型);原文未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,阿利吉仑可在特定骨科手术前预防性使用、在严重创伤后治疗性使用,以预防脂肪栓塞后继发的严重肺部病理后遗症。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Fat embolism (FE) and the consequent FE syndrome occurring after trauma or surgery can lead to serious pulmonary injury, including ARDS and death. Current treatment of FE syndrome is limited to supportive therapy. We have shown in a rat model that the renin angiotensin system plays a significant role in the pathophysiology of FE because drugs interfering with the renin angiotensin system, captopril and losartan reduce the histopathologic pulmonary damage. The purpose of the current study was to determine if inhibition of renin by aliskiren, an FDA-approved drug for treating hypertension, would produce effective protection in the same model.

METHODS: The FE model used intravenous injection of the neutral fat triolein in unanesthetized rats. Intraperitoneal injections of saline or aliskiren at either 50 or 100 mg/kg were performed 1 hour after FE induction via triolein. Rats were euthanized at 48 hours, and various histologic stains were used to examine the lungs.

RESULTS: (1) Fibrosis: rats treated with triolein showed significant fibrotic changes with increased collagen and myofibroblast activation (p < 0.0001 for both trichrome and α-smooth muscle actin staining). Aliskiren blocked this inflammatory and profibrotic process to a level indistinguishable from the controls (p < 0.0001 for both trichrome and α-smooth muscle actin staining). (2) Fat: rats treated with triolein showed a statistically significant increase in fat (p = 0.0006). Subsequent aliskiren administration at both doses reduced the size, distribution, and amount of fat droplets (low dose, p = 0.0095; high dose, p = 0.0028). (3) Vessel patency: the low dose of aliskiren blocked the reduction of lumen patency observed after triolein administration (p = 0.0058).

CONCLUSIONS: Aliskiren protected the lungs of rats from gross and histopathologic FE-induced pulmonary damage at 48 hours. Clinical implications include the use of aliskiren both prophylactically (before certain orthopedic procedures) and therapeutically (after severe trauma) to prevent the consequent severe pulmonary pathologic sequelae.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Fletcher AN, Molteni A, Ponnapureddy R, et al. The renin inhibitor aliskiren protects rat lungs from the histopathologic effects of fat embolism. J Trauma Acute Care Surg. 2017. PMID: 28107310. doi:10.1097/TA.0000000000001278

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。